Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,338 shares of the company’s stock after acquiring an additional 1,093 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Protagonist Therapeutics were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its holdings in Protagonist Therapeutics by 353.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company’s stock valued at $153,000 after purchasing an additional 5,202 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Protagonist Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,228,394 shares of the company’s stock valued at $53,850,000 after purchasing an additional 80,639 shares in the last quarter. Walleye Capital LLC lifted its holdings in Protagonist Therapeutics by 209.3% in the 3rd quarter. Walleye Capital LLC now owns 133,816 shares of the company’s stock valued at $2,232,000 after purchasing an additional 90,555 shares in the last quarter. Kynam Capital Management LP lifted its holdings in Protagonist Therapeutics by 86.5% in the 3rd quarter. Kynam Capital Management LP now owns 1,818,657 shares of the company’s stock valued at $30,335,000 after purchasing an additional 843,359 shares in the last quarter. Finally, Braidwell LP purchased a new position in Protagonist Therapeutics in the 3rd quarter valued at about $18,501,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PTGX. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, February 28th. StockNews.com upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $36.00.

Insider Activity

In other news, CEO Dinesh V. Ph D. Patel sold 30,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $31.62, for a total transaction of $948,600.00. Following the sale, the chief executive officer now owns 574,590 shares in the company, valued at $18,168,535.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director William D. Waddill sold 12,975 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $31.34, for a total transaction of $406,636.50. Following the sale, the director now owns 12,000 shares in the company, valued at $376,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 30,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $31.62, for a total transaction of $948,600.00. Following the sale, the chief executive officer now owns 574,590 shares in the company, valued at approximately $18,168,535.80. The disclosure for this sale can be found here. Insiders have sold 83,457 shares of company stock worth $2,553,328 over the last 90 days. Company insiders own 5.00% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $26.06 on Tuesday. Protagonist Therapeutics, Inc. has a one year low of $13.72 and a one year high of $33.34. The company’s 50 day moving average price is $28.03 and its 200 day moving average price is $23.79. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -17.49 and a beta of 2.09.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.05 by $0.39. The business had revenue of $60.00 million during the quarter, compared to analysts’ expectations of $60.00 million. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 1.18 EPS for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.